ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

Source: 
Fierce Biotech
snippet: 

A new, late-phase analysis of the cholesterol-lowering inclisiran—a PCSK9 drug picked up by Novartis through its $9.7 billion acquisition of The Medicines Company—showed that it was able to cut LDL levels by 51% after nearly a year-and-a-half of treatment.